Is Botulinum Toxin Useful in Systemic Sclerosis Related Peripheral Vasculopathy? A Literature Review

Cutolo, 2019, Pathophysiology of systemic sclerosis: current understanding and new insights, Expert Rev Clin Immunol, 1 Mostmans, 2017, The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review, Autoimmun Rev, 16, 774, 10.1016/j.autrev.2017.05.024 Wigley, 2016, Raynaud's phenomenon, N Engl J Med, 375, 556, 10.1056/NEJMra1507638 Pearson, 2018, Systemic sclerosis: current concepts of skin and systemic manifestations, Clin Dermatol, 36, 459, 10.1016/j.clindermatol.2018.04.004 Volkmann, 2019, Emerging targets of disease-modifying therapy for systemic sclerosis, Nat Rev Rheumatol, 15, 208, 10.1038/s41584-019-0184-z Iorio, 2012, Botulinum toxin A treatment of Raynaud's phenomenon: a review, Semin Arthritis Rheum, 41, 599, 10.1016/j.semarthrit.2011.07.006 Zebryk, 2016, Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review, AMS, 12, 864 Bello, 2017, The therapeutic efficacy of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial, Arthritis Rheumatol (Hoboken, NJ), 69, 1661, 10.1002/art.40123 Motegi, 2017, Efficacy of botulinum toxin b injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis, Acta Derm Venereol, 97, 843, 10.2340/00015555-2665 Uppal, 2014, A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma, J Hand Surg Eur Vol, 39, 876, 10.1177/1753193413516242 Motegi, 2016, Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study, J Dermatol, 43, 56, 10.1111/1346-8138.13030 Serri, 2013, Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis, Ann Chir Plast Esthet, 58, 658, 10.1016/j.anplas.2011.11.001 Dressler, 2012, Clinical applications of botulinum toxin, Curr Opin Microbiol, 15, 325, 10.1016/j.mib.2012.05.012 Nagi, 2017, Botulinum toxin in the management of head and neck disorders, Oral Surg Oral Med Oral Pathol Oral Radiol, 123, 419, 10.1016/j.oooo.2016.11.009 Awan, 2017, The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions – an evidence based review, Saudi Pharm J, 25, 18, 10.1016/j.jsps.2016.04.024 Patil, 2016, Botulinum toxin: pharmacology and therapeutic roles in pain states, Curr Pain Headache Rep, 20, 15, 10.1007/s11916-016-0545-0 Park, 2017, Botulinum toxin for the treatment of neuropathic pain, Toxins (Basel), 9 Kermen, 2016, Botulinum toxin for chronic pain conditions, Dis Mon, 62, 353, 10.1016/j.disamonth.2016.05.011 Flavahan, 2015, A vascular mechanistic approach to understanding Raynaud phenomenon, Nat Rev Rheumatol, 11, 146, 10.1038/nrrheum.2014.195 Cutolo, 2017, Points to consider-Raynaud's phenomenon in systemic sclerosis, Rheumatology (Oxford), 56, v45, 10.1093/rheumatology/kex199 Varju, 2008, Cross-cultural adaptation of the disabilities of the arm, shoulder, and hand (DASH) questionnaire into Hungarian and investigation of its validity in patients with systemic sclerosis, Clin Exp Rheumatol, 26, 776 Poole, 2011, Arthritis Care Res (Hoboken), 63, S189, 10.1002/acr.20631